Previous close | 24.01 |
Open | 23.87 |
Bid | 23.70 x 400 |
Ask | 23.80 x 800 |
Day's range | 23.51 - 23.87 |
52-week range | 22.01 - 33.71 |
Volume | |
Avg. volume | 2,063,827 |
Market cap | 4.016B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 7.76 |
EPS (TTM) | 3.06 |
Earnings date | 22 Jul 2024 - 26 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 34.73 |
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) delivered earnings and revenue surprises of -25.42% and 2.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?